OSCR — Oscar Health, Inc.

Is OSCR overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Healthcare Plans

Neutral As of November 17, 2026

Oscar Health, Inc. (OSCR) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Healthcare Plans) last closed at $31.33. The rating moved from Oversold to Neutral on November 16, 2026.

AI analysis

Oscar Health, Inc. (OSCR) shows a clear growth pathway driven by expansion into Medicare Advantage and continued focus on technology-enabled member engagement and cost management. Recent corporate disclosures and constructive market sentiment provide near-term support, while progress on underwriting margins and enrollment execution are key catalysts. However, proposed CMS regulatory tightening (including RADV/enrollment verification) elevates compliance and clawback risk, and competitive pressures plus medical cost inflation remain material headwinds. Near-term monitoring should prioritize upcoming earnings, enrollment metrics, regulatory developments, and any updates to MA program oversight that could affect cash flow and margin sustainability.

Key factors

  • Medicare Advantage and individual market expansion potential as a growth vector, including product innovation and targeted benefits to attract enrollees
  • Technology-enabled platform for member engagement, care navigation and cost management that can improve unit economics and retention
  • Improving revenue diversification through partnerships and potential moves into group/MA segments that can raise premium scale
  • Recent corporate disclosure (8-K) and neutral-to-positive social sentiment provide near-term reputational/support signals
  • Market environment shows cautious risk-on tone which can support selective flows into growth names with improving fundamentals
  • Operational focus on margin improvement and underwriting performance has trended positively in recent reporting cycles (implying pathway to sustainable profitability)

Risks

  • CMS proposed anti-fraud/regulatory package (stronger RADV and verification) increases risk of payment clawbacks and higher compliance costs that can compress MA economics
  • Medical cost inflation or adverse claims trends could erode underwriting margins and require premium increases that hurt competitiveness
  • Intense competition from large incumbent insurers and vertically integrated health systems that have scale advantages in MA and commercial markets
  • Enrollment volatility and adverse selection if benefit/design changes or marketing mis-execution occur
  • Execution risk on scaling MA product offerings and managing provider network relationships while maintaining unit economics
  • Capital and liquidity constraints in a stressed claims environment or if access to reinsurance/retro arrangements tightens
  • Regulatory, audit and political scrutiny tied to marketplace enrollment integrity and billing practices

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for OSCR — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.